Prof. Dr. Yong Ling received his PhD from China Pharmaceutical University in 2010 and is currently a Professor and doctoral supervisor at the School of Pharmacy, Nantong University, China. He has developed theranostic systems for cancer and inflammatory diseases. His research also focuses on disease-microenvironment-responsive small-molecule theranostics and precision intervention for ischemic stroke. He has published 120+ SCI papers in journals such as Advanced Functional Materials, Chemical Engineering Journal, Journal of Medicinal Chemistry, Theranostics, Green Chemistry, ACS Applied Materials & Interfaces, and Organic Letters, with 30+ CAS Q1 papers and 3,000+ citations (H-index: 34), and holds 60+ granted invention patents (5 international), 20+ licensed to industry. Prof. Ling has been ranked among the World's Top 2% Scientists for three consecutive years (2023–2025), and was selected for the Jiangsu '333 High-Level Talent Program', the 'Six Talent Peaks' Program, and the 'Double Innovation Plan'. He is a member of the Chinese Pharmaceutical Association and the Chinese Chemical Society, a council member of the Nantong Pharmaceutical Association.